Virtu Financial’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Virtu Financial’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-378	Closed	-$13K	–	2297
2022 Q4	$13K	Buy	+378	New	+$45.4K	﹤0.01%	1351
2022 Q2	–	Sell	-1,816	Closed	-$452K	–	2225
2022 Q1	$452K	Buy	1,816 +1,057	+139%	+$167K	0.03%	428
2021 Q4	$118K	Buy	+759	New	+$147K	0.01%	1064
2020 Q4	–	Sell	-405	Closed	-$99K	–	1891
2020 Q3	$99K	Sell	405 -77	-16%	-$24K	0.02%	718
2020 Q2	$139K	Buy	+482	New	+$142K	0.02%	802

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Virtu Financial's EIGR Position: Q1 2023 in Review

Virtu Financial sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2023, closing a stake of 378 shares — an estimated $13K sold.

Virtu Financial first reported a position in EIGR in Q2 2020 and held it in 5 quarters. The position peaked at $452K in Q1 2022. 71 funds tracked by Wall St. Rank hold EIGR as of Q1 2023.

Virtu Financial reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Virtu Financial sold 378 Eiger BioPharmaceuticals, Inc. shares in Q1 2023, an estimated $13K.
Virtu Financial first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2020 and held it in 5 quarters.
Virtu Financial's Eiger BioPharmaceuticals, Inc. position peaked at $452K in Q1 2022.
71 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2023.

Based on Virtu Financial's 13F filing for Q1 2023, filed 1 May 2023.